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Background: Warfarin is a mainstay of therapy for conditions associated with an increased risk of
thromboembolic events. However, the use of this common agent is fraught with complications and little is
known regarding inter-individual variation in warfarin response.
Objective: We tested for association between single nucleotide polymorphisms (SNPs) in VKORC1 and
CYP2C9 and average weekly warfarin dose required to maintain patients at their desired anticoagulation
target.
Methods: The sample consisted of 93 European-American patients from anticoagulation clinics at the
University of North Carolina at Chapel Hill. Data on mean weekly warfarin dose were collected over a
mean treatment period of 20.6 months. ANCOVA models were used and haplotype analysis was
performed.
Results: Three of six VKORC1 SNPs were found to be very strongly associated with the average warfarin
dose required to achieve the target international normalised ratio (INR; p,0.0001). The mean weekly
dose by genotype ranged from approximately 27 to 47 mg. There was no evidence for an association
between either of the two CYP2C9 polymorphisms studied, CYP2C9*2 and CYP2C9*3. CYP2C9*3 was
significantly (p = 0.05) associated with average warfarin dosage after adjustment for VKORC1*1173.
Conclusions: These results are of considerable clinical interest and confirm recently published results
regarding the role of these two genes in modifying warfarin metabolism and maintenance dosage. The
consistent findings regarding the role of VKORC1 and CYP2C9 in warfarin metabolism and maintenance
dosage represent a clinically useful proof of principal for the use of pharmacogenomic information in
medicine and may lead to improved understanding of warfarin’s actions.
I
ndividuals vary widely in their response to pharmacologic
agents and such variability can have profound health
effects. Little is known about drug-specific genetic differ-
ences which lead to differential effects of commonly
prescribed agents. Warfarin is a mainstay of therapy for
conditions which result in an increased risk of thromboem-
bolic events and is used by more than 1 million patients each
year in the US. However, the use of this common agent is
fraught with complications. Following initiation of warfarin
therapy, major bleeding episodes occur in approximately 12%
of patients and death results in as many as 2% of patients.1 2
Although computer aids, nomograms, and flexible proto-
cols3 4 result in improved control of anticoagulation, deter-
mining a patient’s optimal dose remains highly problematic.
Guidance regarding how a given individual will respond to a
standard dose of warfarin promises increased efficacy and
decreased complications associated with the use of this
widely prescribed drug.
Warfarin exerts it pharmacologic effect through its ability
to disrupt the c-glutamyl carboxylation of clotting factors II,
VII, IX, and X. The c-glutamyl carboxylase enzyme requires
reduced vitamin K as a cofactor and warfarin inhibits
regeneration of reduced vitamin K by targeting the enzyme
vitamin K epoxide reductase. The vitamin K epoxide
reductase gene (VKORC1) was cloned in 2004.5 6 The
VKORC1 gene (GI:41352830) is on human chromosome
16p11.2 and encodes a protein of 163 amino acids with a
mass of 18.2 kDa. Although this gene has only recently been
studied, several articles7–12 have already reported evidence for
an association between VKORC1 genotypes and warfarin
dosage.
A second gene, cytochrome P450, subfamily IIC, polypep-
tide 9 (CYP2C9), has been more widely studied in relation to
warfarin sensitivity, due to its involvement in metabolism of
the drug. Two commonly studied variants in CYP2C9
(CYP2C9*2 and CYP2C9*3) have consistently been shown to
be associated with warfarin dosage. Sanderson et al presented
a meta-analyses of these results from nine different studies.13
The results from the meta-analyses demonstrate that patients
with the CYP2C9*2 and CYP2C9*3 variant alleles have lower
mean daily warfarin dosage and greater risk of bleeding.
We sought to confirm whether genetic variation in the
VKORC1 and CYP2C9 genes influences an individual’s
sensitivity to warfarin in a sample of European-American
anticoagulation clinic patients, as well as to examine whether
the VKORC1 genetic effects were independent of the two
CYP2C9 polymorphisms that have been established to be
associated with warfarin sensitivity.
METHODS
This study was approved by the Biomedical Institutional
Review Board at the University of North Carolina at Chapel
Hill. Patients attending anticoagulation clinics at UNC who
were being treated with warfarin were approached for
Abbreviations: ANCOVA, analysis of covariance; INR, international
normalised ratio; LD, linkage disequilibrium; SNP, single nucleotide
polymorphism; VTE, venous thromboembolic events
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participation in the current study. After obtaining informed
consent, blood was obtained from 93 European-American
patients for DNA analysis. An extensive database is main-
tained on these patients that includes the indication for
treatment, duration of treatment, average dose, dosage
adjustments, and international normalised ratio (INR).
Mean weekly warfarin dose required to achieve each patient’s
target INR was gathered from the database over a mean
period of treatment of 20.6 months. Genomic DNAs were
extracted from whole blood using the QIAamp DNA Blood
Mini Kit (Qiagen, Valencia, CA).
Genomic sequencing
Direct sequencing of 60 patients identified six single
nucleotide polymorphisms (SNPs) in the VKORC1 gene.
Approximately 10 ng DNA was used for PCR reactions. The
primers used to amplify the 59-UTR and exon 1 region were:
CCAATCGCCGAGTCAGAGG and CCCAGTCCCCAGCACTGT-
CT; primers for exon 2 and flanking region were:
AGGGGAGGATAGGGTCAGTG and CCTGTTAGTTACCTCCC-
CACA; and primers for exon 3 and the 39-UTR were:
ATACGTGCGTAAGCCACCAC and ACCCAGATATGCCCCCT-
TAG. Sequencing was via high throughput capillary electro-
phoresis. Genotyping for these SNPs was then performed in
the remaining patients.
Assay of known SNPs was via real time PCR. The assay
reagents for SNP genotyping were obtained from the Assay-
by-Design service (Applied Biosystems, Foster City, CA). The
primers and probes (FAM and VIC dye-labelled) were
designed using Primer Express software and were synthe-
sised in Applied Biosystems (table 1). PCR reactions used 26
TaqMan Universal PCR Master Mix, No AmpErase UNG
(Applied Biosystems). The real time PCR reactions were
performed in an Opticon II system (Bio-Rad Laboratories/MJ
Research, Waltham, MA). Conditions were as follows: 95 C̊
10 min preheat, 92 C̊ 15 s, 60 C̊ 1 min followed by a plate
reading, 40 cycles. The results were read according to the
signal value of FAM and VIC dye.
Statistical methods
Each of the SNPs was first assessed to determine if the
observed genotype frequencies were consistent with expected
Hardy-Weinberg proportions using Pearson’s x2 tests. Pair-
wise marker-marker linkage disequilibrium was assessed
using Lewontin’s D9 statistic14 and Devlin and Risch’s D2
statistic15 as implemented in the computer program GOLD
(www.sph.umich.edu/csg/abecasis/GOLD).
To test for association between individual SNPs and the
continuously distributed outcomes, average warfarin dose,
and average INR, we performed analysis of covariance
models (ANCOVA) using PROC GLM within the SAS
software system (version 8.0, SAS Institute, Cary, NC). The
outcomes were first examined for adherence to distributional
assumptions (including approximate normality of error terms
conditional on covariates and homoscedasticity); the natural
log transformation was subsequently applied to average
dosage to adhere to these assumptions. Covariate adjustment
was made for age, gender, and target INR in all analytic
models. Genotype was tested for general association (no
mode of inheritance assumption) using a 2 df F test. A 1 df F
test was used to test the null hypotheses of no association for
the CYP2C9 genotypes due to a lack of observed homozygotes
for the CYP2C9*2 or *3 alleles. We additionally examined a
two locus model, in which we selected the most statistically
significant polymorphism from each of the two genes and
tested the effects of each while controlling for the other.
Finally, a model testing the interaction effects between the
two polymorphisms was performed.
Tests of haplotype effects were performed using a score test
developed by Schaid, as implemented in the computer
program HAPLO.STAT (http://mayoresearch.mayo.edu/mayo/
research/biostat/schaid.cfm). HAPLO.STAT utilises a weight-
ing scheme based on EM derived haplotype frequency
estimates and weights every haplotype rather than assigning
a ‘‘most likely’’ haplotype to an individual. Statistical
differences in overall haplotype frequencies (excluding
haplotypes with extremely low frequencies, for example
0.01) were tested, after adjustment for covariates (age,
gender, and target INR), for association with the outcomes.
Specific individual haplotype effects were also tested.
RESULTS
The sample consisted of 93 European-American subjects with
both genotype and phenotype data. The mean age was
63 years (SD 16, range 24–90 years) and 31% (n = 29) of the
subjects were female. Mean treatment period for this study
was 20.6 months (SD 11.0, range 12 days to 37.3 months).
Indications for warfarin were predominantly atrial fibrilla-
tion or atrial flutter (45%, n = 47), with another large group
(26%, n = 24) being treated or prophylaxed for venous
thromboembolic events (VTE). Thirteen (14%) of the patients
were receiving warfarin due to prosthetic mitral or aortic
valves. The target INR for the majority of patients (83%,
n = 77) was 2–3. Three of the prophylaxed VTE patients had a
goal of 1.5–2.0. Thirteen patients had a goal of 2.5–3.5; this
group included those with a prosthestic mitral valve as well
as those with both a prosthetic atrial valve and atrial
fibrillation. The positions and the corresponding observed
allele frequencies of the identified SNPs in all 93 patients are
given in table 2. The observed distributions of genotype data
for the VKORC1 and CYP2C9 SNPs were consistent with
expected Hardy-Weinberg proportions (data not shown).
Table 3 displays the association results of the six VKORC1
polymorphisms with mean weekly warfarin dose and INR in
these patients. As expected, the observed INRs cluster tightly
around 2.5 since warfarin doses were continually adjusted
clinically in order to achieve an appropriate level of antic-
oagulation, with an INR of 2–3 being the most common
target. Five of the six VKORC1 SNPs were found to be
statistically associated with average warfarin dose required to
achieve the target INR (p ranging from ,0.0001 to 0.021).
The VKORC1*1173, VKORC1*1542, and VKORC1*2255 SNPs
were found to be the most strongly associated with the
average warfarin dose required to achieve the target INR
Table 1 The primers and probes used in real time PCR genotyping
VKOR SNPs VIC probe sequence FAM probe sequence Forward primer Reverse primer
VKOR 497 T.G CCCCTTCaCCTGCGC CCCCTTCcCCTGCGC GCGGTAGAGATTGACGATGGT GCAGCCATCGCCAACAC
VKOR 698 C.T CAAGGCTgGTATAACG CAAGGCTaGTATAACG CTCTGATGCAAAACCGAGTGAAC GCCCGGCCCTTAAGTAATTCTT
VKOR 1173 C.T CCTAGTCCAAGgGTCGAT CTAGTCCAAGaGTCGAT CCCGGTGCCAGGAGATC CACCTGGGCTATCCTCTGTTC
VKOR 1542 G.C TCATCACgGAGCGTC TCATCACcGAGCGTC GGTGATCCACACAGCTGACA CCTGTTAGTTACCTCCCCACATC
VKOR 2255 T.C CCAGGACCaTGGTGC CCAGGACCgTGGTGC GCTCCAGAGAAGGCATCACT GCCAAGTCTGAACCATGTGTCA
VKOR 3730 G.A ATACCCgCACATGAC CATACCCaCACATGAC GTCCCTAGAAGGCCCTAGATGT GTGTGGCACATTTGGTCCATT
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(p,0.0001). The trend in mean warfarin dosage by all three
genotypes is consistent with an additive mode of inheritance,
where the mean for the heterozygote is roughly midway
between the two homozygotes
The VKORC1*1173, *1542, and *2255 SNPs were found to
be in very strong linkage disequilibrium (LD) with each
other, with estimated D9 values of 1.00 and estimated D2
values ranging from 0.94 to 0.98. Estimated D9 values ranged
from 0.84 to 1.00 and estimated D2 values ranged from 0.11
to 0.56 for all other SNP pair combinations. Haplotype
analysis results are reported in table 4. Four haplotypes were
observed with an estimated frequency greater than 3%. The
permutation based global p value for any difference between
haplotypes was 0.0004. All four of the individual haplotype
specific tests were found to be statistically significant
(p,0.05). The two haplotypes (EA1 and EA2) characterised
by the T allele for VKOR 1173, the C allele for VKOR 1542, and
the T allele for VKOR 2255 were associated with negative
score statistics (indicating lower mean dosage), while the
other two haplotypes were associated with positive score
statistics (indicating higher mean dosage). Overall, the
haplotype results are consistent with the single SNP results
and suggest that the causal polymorphism is one of the
identified SNPs (VKORC1*1173, *1542, or *2255) or another
polymorphism in LD with these three SNPs.
The CYP2C9 SNP association results are presented in table 5.
Only 14 and 13 heterozygotes were observed for CYP2C9*2
and CYP2C9*3 polymorphisms, respectively. There was no
evidence for an association between CYP2C9 genotypes and
average warfarin weekly dose before additional adjustment
for VKORC1 genotype. CYP2C9*3 became marginally statisti-
cally significant (p = 0.050) after adjustment for VKOR 1173.
The CYP2C9*2 and CYP2C9*3 SNPs were not found to be in
significant LD with one another (D9 = 0.04, D2 = 0.00,
p = 0.97). Given the lack of LD between the two SNPs,
haplotype analyses were not performed.
DISCUSSION
We have here shown that variants within VKORC1 are
strongly associated with the mean weekly dose of warfarin
required to maintain a desired target INR in a sample of
European-American outpatients undergoing anticoagulation
treatment. In addition to their robust statistical significance,
the results presented here are potentially clinically mean-
ingful given the notoriously narrow therapeutic window16 of
the drug in question. The mean weekly dose of warfarin
required to maintain the desired target INR is almost doubled
(from 27 to 47 mg) for those who are homozygous C/C at
position 1173, G/G at position 1542, or C/C at position 2255,
as compared with the homozygotes for the opposite allele at
each site. Also bolstering the significance of these results is
the dose-response curve observed in heterozygotes, who
demonstrate intermediate warfarin sensitivity. Moreover,
these alleles are common in this unselected sample with an
estimated prevalence of 54.2% for the VKORC1*1173 C allele,
55.7% for the VKORC1*1542 G allele, and 54.7% for the
VKORC1*2255 C allele. These results are strongly consistent
with recent findings regarding the effects of VKORC1
genotype on warfarin dosage levels required to reach desired
INR both in terms of overall statistical significance and mean
warfarin dosage levels by genotype.7–12 For example,
D’Andrea et al7 report an observed warfarin mean weekly
dosage of 49.0, 35.7, and 25.9 (calculated by multiplying their
reported mean daily dosage by 7) for VKORC1*1173 genotypes
C/C, C/T, and T/T, respectively, as compared with our
observed weekly mean dosages of 47.1, 35.8, and 26.9,
respectively, for the same genotypes. In addition, there is
considerable agreement with the direction of the haplotype
based associations. In our study, EA1 and EA2 are associated
with lower mean levels of warfarin dosage and haplotypes
EA3 and EA4 are associated with higher mean levels of
warfarin dosage. Our haplotyes EA1 and EA2 have identical
alleles as do haplotypes H3a and H3b in Wadelius et al10 for
VKORC1*1173, *2255, and *3730. Our haplotype EA3 corre-
sponds to H2 and our haplotype EA4 corresponds to H1 in
Wadelius et al,10 where H1 and H2 are also associated with
higher warfarin dosage. Finally, our haplotypes EA1, EA2,
EA3, and EA4 correspond to the sets of haplotypes {H2, H5},
{H1, H3}, {H4, H6, H9}, and {H7, H8}, respectively, in Rieder
et al8; the direction of results between the two studies with
respect to which haplotypes are associated with higher or
lower warfarin dosage levels is also entirely consistent.








VKORC1*497 T.G Intron 1 Rs2884737 68.8
VKORC1*698 C.T Intron 1 Rs17708472 79.6
VKORC1*1173 C.T Intron 1 Rs9934438 54.8
VKORC1*1542 G.C Intron 2 Rs8050894 56.5
VKORC1*2255 T.C Intron 2 Rs2359612 44.1







Six SNPs were identified in the VKORC1 gene upon sequencing and real
time PCR among 93 individuals. The location and allelic frequency of
each SNP is shown.










TT 43 43.6 2.5
TG 42 34.4 2.7
GG 8 24.9 2.7
p value 0.0015 0.12
698 C.T
CC 59 35.2 2.7
CT 30 40.0 2.5
TT 4 54.7 2.4
p value 0.056 0.18
1173 C.T
CC 31 47.1 2.5
CT 40 35.8 2.6
TT 22 26.9 2.7
p value ,0.0001 0.10
1542 G.C
GG 32 46.4 2.5
GC 41 36.0 2.6
CC 20 26.5 2.7
p value ,0.0001 0.11
2255 T.C
TT 20 26.5 2.7
TC 42 35.7 2.6
CC 31 47.1 2.5
p value ,0.0001 0.11
3730 G.A
GG 40 33.3 2.6
GA 40 39.7 2.6
AA 13 46.4 2.5
p value 0.021 0.63
Least-square means are on the untransformed data and p values were
obtained using the log transformation. All models adjusted for age and
gender. Models for average weekly dose of warfarin additionally
adjusted for target INR.
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In addition to our VKORC1 results, we did not detect a
statistically significant association between the two CYP2C9
polymorphisms and warfarin dosage before adjustment for
VKORC1; however, results for CYP2C9*3 did reach a marginal
level of statistical significance (p = 0.05) after adjustment for
VKORC1*1173. Because the CYP2C9 SNPs have lower minor
allele frequencies than the VKORC1 SNPs examined, the
power to detect significant departures from the null hypoth-
esis of no association for CYP2C9 was less than that for
VKORC1.
In previously reported work, Sconce et al9 demonstrated the
best multivariable regression model for fitting warfarin
dosage included both CYP2C9 and VKORC1. Our multivariable
model including age, gender, target INR, and VKORC1*1173
genotype explained approximately 30% (R2 = 0.30) of our
total observed variation. Our multivariable model including
age, gender, target INR, and CYP2C9*3 explained only 12% of
the total variation. Including both CYP2C9*3 and
VKORC1*1173 along with our covariates explained 34% of
the total variation. Thus, our multivariable model appeared to
explain less of the total variation in the mean warfarin
dosage required to reach the target INR than the multi-
variable regression model of Sconce et al9 (R2 = 0.55). It
should be noted that their model included height, a measure
that we did not have available to us for this study. In
addition, our results suggest, consistent with the findings of
Wadelius et al10, that VKORC1 polymorphisms explain a larger
amount of the observed variation in mean warfarin dosage
required to reach the target INR than do CYP2C9 polymorph-
isms in the European-American population.
During the course of our study, we also collected data on
warfarin dosage requirements to reach the target INR for 18
African-Americans. Of these 18 patients, one had a target
INR of 1.5–2.0, 14 had a target INR of 2.0–3.0, and three had
a target INR of 2.5–3.5. Marginally statistically significant
results were observed for VKORC1*1173 (p = 0.03) and *2255
(p = 0.03) and CYP2C9*3 (p = 0.01) in this limited data set.
These results could be entirely explained by the low observed
warfarin dosages (average weekly dosage of 9.3 mg) of a
single individual who was homozygous T/T at both
VKORC1*1173 and *2255 and heterozygous at CYP2C9*3.
This individual’s genotypes at these three markers were
consistent with the genotypes that were shown to be
associated with low warfarin dosage in the European-
American population. In addition, this individual had the
lowest target INR (1.75) and was also the only African-
American individual in our sample with these aforemen-
tioned genotypes. We note that in our limited sample, there
were strong differences in allele frequencies (data not
shown) between the European-American and African-
American samples. For example, VKORC1*698 and CYP2C9*2
were uninformative (completely homozygous for the wild
type allele) in this small African-American sample. We also
note that we observed weaker marker-marker LD and a larger
diversity in haplotypes in this limited African-American
sample (data not shown). These findings are all consistent
with the comparative results between the European and
African-Yoruban samples genotyped at VKORC1 as part of the
International HapMap Project (www.hapmap.org). While
these results based on 18 African-American patients are
limited and inconclusive, they do suggest that it is important
to assess the role of VKORC1 SNPs in warfarin response in
other populations and that studying different populations
with different haplotype patterns may be critical in ultimately
identifying the functionally important variants.
It remains undetermined whether one or more of the SNPs
identified here or elsewhere are causal in producing
differential warfarin sensitivity or whether they are in LD
with the actual causative SNP. Strong LD between VKORC1
polymorphisms in the European-American population hin-
ders our ability to fine map/identify the functional loci.
Further analysis of warfarin related gene(s) and surrounding
sequence and the inclusion of larger numbers of patients,
ideally in different populations, may lead to elucidation of
the specific genotypic factors which influence warfarin
sensitivity. In addition, prospective studies will ultimately
be critical to establishing the clinical utility of assessing
VKORC1 genotype for determining optimal warfarin dosage.
Nonetheless, combining genotype data from SNPs of the
VKORC1 gene with SNPs of the cytochrome CYP2C9 gene in a
clinical setting promises to result in a more robust assess-
ment of warfarin sensitivity.
The results presented here support those from other recent
reports7–12 and further demonstrate the need for prospective
studies to evaluate the utility of VKORC1 and CYP2C9
genotype information with respect to outcomes such as
length of time until the target INR is reached and adverse
events. This current demonstration of common polymorph-
isms that predict warfarin sensitivity represents a potentially
clinically useful proof of principal for the use of pharmaco-
genomic information in medicine and will likely play a
Table 4 Association between VKORC1 gene haplotypes and log average dose
Haplotype
VKORC1 gene SNPs
Score* p497 698 1173 1542 2255 3730 Estimated frequency (%)
EA1 G C T C T G 30.1 23.42 0.00063
EA2 T C T C T G 12.9 22.26 0.024
EA3 T T C G C G 19.3 2.47 0.013
EA4 T C C G C A 34.9 2.73 0.0063
Global` 0.0004
*HAPLO.STAT (http://mayoresearch.mayo.edu/mayo/research/biostat/schaid.cfm) program statistic; haplotype specific empirical p values comparing each
specific haplotype to all others combined; `simulated p value for global association test.
Table 5 Association between CYP2C9 genotypes and














11 79 38.8 37.3 2.6
12 14 32.1 31.0 2.6
22 0 – – –
p value 0.19 0.16 0.93
CYP2C9*3
11 80 38.5 37.1 2.6
12 13 33.0 31.5 2.7
22 0 – – –
p value 0.24 0.050 0.12
All models adjusted for age and gender. Models for average weekly dose
of warfarin were additionally adjusted for the target INR.
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critical role in future predictive models for warfarin dosage.
Such models will have strong potential to guide physicians in
quickly prescribing appropriate dosages and, ultimately,
avoid complications.
ELECTRONIC-DATABASE INFORMATION
Information about the computer program GOLD is at
www.sph.umich.edu/csg/abecasis/GOLD, the
computer program HAPLO.STAT at
http://mayoresearch.mayo.edu/mayo/research/
biostat/schaid.cfm, and the International HapMap
Project at www.hapmap.org.
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